<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:52:57Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4020789" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4020789</identifier><datestamp>2014-06-05</datestamp><setSpec>nihpa</setSpec><setSpec>pmc-open</setSpec><setSpec>manuscript</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
      <journal-id journal-id-type="nlm-ta">Nature</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
      <journal-title-group>
        <journal-title>Nature</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-0836</issn>
      <issn pub-type="epub">1476-4687</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4020789</article-id>
      <article-id pub-id-type="pmcid">PMC4020789</article-id>
      <article-id pub-id-type="pmc-uid">4020789</article-id>
      <article-id pub-id-type="pmid">24256733</article-id>
      <article-id pub-id-type="pmid">24256733</article-id>
      <article-id pub-id-type="doi">10.1038/nature12735</article-id>
      <article-id pub-id-type="manuscript">nihpa529325</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Activation and allosteric modulation of a muscarinic acetylcholine receptor</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kruse</surname>
            <given-names>Andrew C.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN2" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ring</surname>
            <given-names>Aaron M.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref rid="FN2" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manglik</surname>
            <given-names>Aashish</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>Jianxin</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hu</surname>
            <given-names>Kelly</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Eitel</surname>
            <given-names>Katrin</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>HÃ¼bner</surname>
            <given-names>Harald</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pardon</surname>
            <given-names>Els</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Valant</surname>
            <given-names>Celine</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sexton</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Christopoulos</surname>
            <given-names>Arthur</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Felder</surname>
            <given-names>Christian C.</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gmeiner</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Steyaert</surname>
            <given-names>Jan</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Weis</surname>
            <given-names>William I.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garcia</surname>
            <given-names>K. Christopher</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wess</surname>
            <given-names>JÃ¼rgen</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kobilka</surname>
            <given-names>Brian K.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 279 Campus Drive, Stanford, CA 94305 USA</aff>
      <aff id="A2"><label>2</label>Department of Structural Biology, Stanford University School of Medicine, 299 Campus Drive, Stanford, CA 94305 USA</aff>
      <aff id="A3"><label>3</label>Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA</aff>
      <aff id="A4"><label>4</label>Department of Chemistry and Pharmacy, Friedrich Alexander University, Schuhstrasse 19, 91052 Erlangen, Germany</aff>
      <aff id="A5"><label>5</label>Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, B-1050 Brussels, Belgium; Structural Biology Research Centre, VIB, Pleinlaan 2, B-1050 Brussels, Belgium</aff>
      <aff id="A6"><label>6</label>Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia</aff>
      <aff id="A7"><label>7</label>Neuroscience, Eli Lilly &amp; Co., Indianapolis, IN 46285</aff>
      <author-notes>
        <corresp id="FN1">Correspondence and requests for materials should be addressed to B.K.K. (<email>kobilka@stanford.edu</email>)</corresp>
        <fn id="FN2" fn-type="equal">
          <label>*</label>
          <p>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>2</day>
        <month>4</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>11</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>5</day>
        <month>12</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>05</day>
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <volume>504</volume>
      <issue>7478</issue>
      <fpage>101</fpage>
      <lpage>106</lpage>
      <!--elocation-id from pubmed: 10.1038/nature12735-->
      <permissions>
        <license>
          <license-p>Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: 
<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P1">Despite recent advances in crystallography of G protein-coupled receptors (GPCRs), little is known about the mechanism of their activation process, as only the Î²<sub>2</sub> adrenergic receptor (Î²<sub>2</sub>AR) and rhodopsin have been crystallized in fully active conformations. Here, we report the structure of an agonist-bound, active state of the human M<sub>2</sub> muscarinic acetylcholine receptor stabilized by a G-protein mimetic camelid antibody fragment isolated by conformational selection using yeast surface display. In addition to the expected changes in the intracellular surface, the structure reveals larger conformational changes in the extracellular region and orthosteric binding site than observed in the active states of the Î²<sub>2</sub>AR and rhodopsin. We also report the structure of the M<sub>2</sub> receptor simultaneously binding the orthosteric agonist iperoxo and the positive allosteric modulator LY2119620. This structure reveals that LY2119620 recognizes a largely pre-formed binding site in the extracellular vestibule of the iperoxo-bound receptor, inducing a slight contraction of this outer binding pocket. These structures offer important insights into activation mechanism and allosteric modulation of muscarinic receptors.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="S1">
      <title>Introduction</title>
      <p id="P2">Muscarinic acetylcholine receptors (M<sub>1</sub> â M<sub>5</sub>) are GPCRs that regulate the activity of a diverse array of central and peripheral functions in the human body, including the parasympathetic actions of acetylcholine<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. The M<sub>2</sub> muscarinic receptor subtype plays a key role in modulating cardiac function and many important central processes, such as cognition and pain perception<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. As it was among the first GPCRs to be purified<sup><xref rid="R2" ref-type="bibr">2</xref></sup> and cloned<sup><xref rid="R3" ref-type="bibr">3</xref></sup>, the M<sub>2</sub> receptor has long served as a model system in GPCR biology and pharmacology. Muscarinic receptors have attracted particular interest due to their ability to bind small molecule allosteric modulators<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. Since allosteric sites are often less conserved than the orthosteric binding site, some ligands binding to allosteric sites show substantial subtype selectivity<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup>. Such agents hold great promise for the development of drugs for the treatment of conditions, including diseases of the central nervous system and metabolic disorders. Though crystal structures were recently obtained for inactive states of the M<sub>2</sub> and M<sub>3</sub> muscarinic receptors<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup>, there are no structures of a GPCR bound to an allosteric modulator.</p>
      <p id="P3">The binding of an agonist to the extracellular side of a GPCR results in conformational changes that enable the receptor to activate heterotrimeric G proteins. Despite the importance of this process, only the Î²<sub>2</sub>AR and rhodopsin have been crystallized in fully active conformations<sup><xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R13" ref-type="bibr">13</xref></sup>. Crystallization of active-state GPCRs has been challenging due to their inherent conformational flexibility and biochemical instability<sup><xref rid="R14" ref-type="bibr">14</xref></sup>. To better understand the mechanistic details underlying GPCR activation and allosteric modulation, we solved X-ray crystal structures of the M<sub>2</sub> receptor bound to the high affinity agonist iperoxo<sup><xref rid="R15" ref-type="bibr">15</xref></sup> alone and in combination with LY2119620, a positive allosteric modulator.</p>
    </sec>
    <sec id="S2">
      <title>Conformational selection of nanobodies</title>
      <p id="P4">Initial crystallization attempts with M<sub>2</sub> receptor bound to agonists were unsuccessful, likely due to the flexibility of the intracellular receptor surface in the absence of a stabilizing protein. We thus sought to obtain a âG protein mimeticâ nanobody for the M<sub>2</sub> receptor to facilitate crystallization of the Î²<sub>2</sub>AR in an active conformation<sup><xref rid="R11" ref-type="bibr">11</xref></sup>. Llamas were immunized with M<sub>2</sub> receptor bound to the agonist iperoxo, and a post-immune single variable domain (V<sub>HH</sub>) nanobody cDNA library was constructed and displayed on the surface of yeast (<xref rid="F1" ref-type="fig">Fig. 1a</xref>).</p>
      <p id="P5">An essential component for the selection of active-state stabilizing nanobodies was simultaneous staining of yeast with both agonist and inverse-agonist occupied M<sub>2</sub> receptor populations, which were distinguishably labeled with separate fluorophores. This allowed the use of fluorescence-activated cell sorting (FACS) to select those clones binding only agonist-occupied receptor (<xref rid="F1" ref-type="fig">Fig. 1b</xref>; see Online Methods). To ensure that the different fluorophore-conjugated receptors represent distinct receptor populations requires that at least one receptor population must be bound to an exceptionally high-affinity or irreversible ligand. We therefore developed a covalent muscarinic receptor agonist for use in selection experiments. This has precedent in an acetylcholine mustard<sup><xref rid="R16" ref-type="bibr">16</xref></sup>, which is thought to react with the binding site residue Asp103<sup>3.32</sup> to form a covalent adduct<sup><xref rid="R17" ref-type="bibr">17</xref></sup>. Accordingly, we synthesized an analogous âiperoxo mustard,â which we call FAUC123 (<xref rid="SD1" ref-type="supplementary-material">Supplementary Methods</xref>). We found that FAUC123 bound covalently and was able to induce activation of the M<sub>2</sub> receptor (<xref rid="F6" ref-type="fig">Extended Data Fig. 1</xref>), thereby allowing simultaneous staining of yeast with agonist- and antagonist-bound M<sub>2</sub> receptor labeled with distinct fluorophores for each population.</p>
      <p id="P6">After nine rounds of conformational selection, almost all remaining yeast cell clones preferentially bound FAUC123-occupied receptor (<xref rid="F1" ref-type="fig">Fig. 1d</xref>). Three clones in particular, Nb9-1, Nb9-8, and Nb9-20 (<xref rid="F2" ref-type="fig">Fig. 2a</xref>; see Online Methods) exhibited strong, conformationally-selective staining on yeast (<xref rid="F2" ref-type="fig">Fig. 2b</xref>). All three nanobodies enhanced agonist affinity (<xref rid="F2" ref-type="fig">Fig. 2c</xref>), indicating that they stabilize active states of the receptor. Nb9-8 was the most potent, with an EC<sub>50</sub> of approximately 100 nM. At high concentrations, Nb9-8 enhanced the affinity of the M<sub>2</sub> receptor for iperoxo to almost the same extent as that observed in the presence of the heterotrimeric G protein G<sub>i</sub> (<xref rid="F2" ref-type="fig">Fig. 2d</xref>).</p>
      <p id="P7">M<sub>2</sub> receptor was purified in the presence of 10 Î¼M iperoxo, and we obtained crystals of iperoxo-bound M<sub>2</sub> receptor in complex with Nb9-8 by lipidic mesophase crystallography. The structure was solved by microdiffraction at Advanced Photon Source beamline 23ID-D (<xref rid="T1" ref-type="table">Extended Data Table 1</xref>). Supplementing the optimized crystallization conditions with the positive allosteric modulator LY2119620 yielded crystals of M<sub>2</sub> receptor simultaneously bound to both iperoxo and the modulator (see Online Methods). For all crystallization work, the agonist iperoxo was used rather than acetylcholine, as the latter is of lower affinity and is prone to hydrolysis.</p>
    </sec>
    <sec id="S3">
      <title>Cytoplasmic changes upon activation</title>
      <p id="P8">A key feature of GPCR activation is an outward movement of the intracellular portion of transmembrane (TM) helices 5 and 6, creating a cavity large enough to accommodate the carboxy terminus of the G protein Î± subunit<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup>. While several GPCRs have been crystallized in complex with agonists, only the Î²<sub>2</sub>AR and rhodopsin show a fully active state with adequate space to allow G protein binding (<xref rid="F7" ref-type="fig">Extended Data Fig. 2</xref>). As anticipated based on functional studies (<xref rid="F2" ref-type="fig">Fig. 2</xref>), Nb9-8 binds to the intracellular surface of the receptor (<xref rid="F3" ref-type="fig">Fig. 3a</xref>). There is a significant outward displacement at the intracellular side of TM6, together with a smaller outward movement of TM5 and a rearrangement of TM7 around the NPxxY motif (<xref rid="F3" ref-type="fig">Fig. 3b, d</xref>).</p>
      <p id="P9">Like the active states of rhodopsin and the Î²<sub>2</sub>AR, the active M<sub>2</sub> receptor shows rearrangements of the highly conserved DRY motif at the intracellular side of TM3 and the NPxxY motif in TM7 (<xref rid="F3" ref-type="fig">Fig. 3c, d</xref>). In the active state of M<sub>2</sub>, Arg121<sup>3.50</sup> of the DRY motif adopts an extended conformation virtually identical to that seen in metarhodopsin II and the Î²<sub>2</sub>AR-G<sub>s</sub> complex (<xref rid="F3" ref-type="fig">Fig. 3c, e</xref>, superscript numerals refer to the Ballesteros-Weinstein numbering system), and Asp120<sup>3.49</sup> is stabilized by a hydrogen bond with Asn58<sup>2.39</sup> (<xref rid="F3" ref-type="fig">Fig. 3c</xref>). To assess the importance of Asn58<sup>2.39</sup> for stabilization of the active conformation, we mutated it to alanine. The resulting mutant displayed normal ligand binding properties, but impaired ability to activate G protein (<xref rid="F8" ref-type="fig">Extended Data Fig. 3a</xref>; <xref rid="T2" ref-type="table">Extended Data Table 2</xref>). Hence, it is likely that Asn58<sup>2.39</sup> either directly stabilizes the active conformation, or engages in direct interactions with G protein.</p>
      <p id="P10">Similar to the DRY motif, the NPxxY region in TM7 shows significant rearrangements on activation (<xref rid="F3" ref-type="fig">Fig. 3d</xref>). Most striking is a partial âunwindingâ of TM7 around Tyr440<sup>7.53</sup>. This positions Tyr440<sup>7.53</sup> of the NPxxY motif in close proximity to the highly conserved residue Tyr206<sup>5.58</sup> (<xref rid="F3" ref-type="fig">Fig. 3d</xref>). Although these two residues are not close enough to directly interact, their proximity may allow formation of a water-mediated hydrogen bond, as seen in the active-state structures of the Î²<sub>2</sub>AR<sup><xref rid="R18" ref-type="bibr">18</xref></sup> and rhodopsin<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. Indeed, the position of these two tyrosine residues is highly similar in the active structures of rhodopsin, Î²<sub>2</sub>AR, and the M<sub>2</sub> receptor (<xref rid="F3" ref-type="fig">Fig. 3f</xref>), suggesting that this feature represents a hallmark of GPCR activation. In addition, a molecular dynamics study recently predicted that Tyr206<sup>5.58</sup> and Tyr440<sup>7.53</sup> interact in the active conformation of the M<sub>2</sub> receptor<sup><xref rid="R19" ref-type="bibr">19</xref></sup>, although this model was in other ways dissimilar from the structures presented here.</p>
      <p id="P11">To assess the importance of this interaction for M<sub>2</sub> receptor activation, we mutated Tyr206<sup>5.58</sup> to phenylalanine, eliminating its ability to interact with Tyr440<sup>7.53</sup> via a bridging water molecule. The Y206F mutant receptor could no longer be activated by acetylcholine (<xref rid="F8" ref-type="fig">Extended Data Fig. 3a</xref>) and gave only a very weak functional response upon treatment with iperoxo. In addition, agonist affinity was reduced by greater than 10-fold (<xref rid="T2" ref-type="table">Extended Data Table 2</xref>), while antagonist binding was largely unaffected. These results suggest that the Tyr206<sup>5.58</sup>-Tyr440<sup>7.53</sup> interaction stabilizes the active conformation of the receptor in a manner reminiscent of the âionic lockâ interaction<sup><xref rid="R20" ref-type="bibr">20</xref></sup>, which stabilizes the inactive conformation of family A GPCRs.</p>
    </sec>
    <sec id="S4">
      <title>Activation mechanism</title>
      <p id="P12">While activation of the Î²<sub>2</sub>AR and rhodopsin is associated with modest conformational changes in the orthosteric ligand-binding site, striking structural changes are observed in the M<sub>2</sub> receptor. The activated M<sub>2</sub> receptor shows a small orthosteric binding site, which completely occludes the agonist iperoxo from solvent (<xref rid="F4" ref-type="fig">Fig. 4a, b</xref>). Indeed, the muscarinic inverse agonist quinuclidinyl benzilate (QNB) is too large to be accommodated in this binding cavity, perhaps accounting for its ability to suppress basal activity of the M<sub>2</sub> receptor.</p>
      <p id="P13">Within the active orthosteric binding pocket, the agonist iperoxo adopts a bent conformation (<xref rid="F4" ref-type="fig">Fig. 4c</xref>; <xref rid="F9" ref-type="fig">Extended Data Fig. 4</xref>). TM helices 5, 6, and 7 move inward, toward the agonist, in the active M<sub>2</sub> conformation. TM3, in contrast, undergoes a slight rotation about its axis, but has almost no inward motion toward the ligand. The largest differences between inactive and active states of the M<sub>2</sub> receptor involve TM6, where an inward movement of 2 Ã at the Î±-carbon of Asn404<sup>6.52</sup> allows for formation of a hydrogen bond between its side chain and iperoxo.</p>
      <p id="P14">Despite these activation-related structural changes, polar contacts between the agonist iperoxo and the receptor resemble those with QNB bound to the inactive M<sub>2</sub> receptor. In particular, the conserved Asp103<sup>3.32</sup> serves as a counter-ion to the ligand amine in both cases, and Asn404<sup>6.52</sup> engages in hydrogen bonding with both ligands. The smaller size of iperoxo relative to QNB results in more limited hydrophobic contacts, however. This is particularly true along TM5, which engages the phenyl rings of QNB, but makes more limited hydrophobic contact with iperoxo in the active receptor conformation.</p>
      <p id="P15">The hydrogen bond between Asn404<sup>6.52</sup> and the iperoxo isoxazoline oxygen is analogous to the hydrogen bond between this residue and the QNB carbonyl in the inactive receptor state; however, the smaller size of iperoxo necessitates an inward motion of TM6 (<xref rid="F4" ref-type="fig">Fig. 4d, e</xref>). To investigate the role of this hydrogen bond in receptor activation, we mutated Asn404<sup>6.52</sup> to glutamine, which, due to the longer side chain, would allow TM6 to form a hydrogen bond with iperoxo in the inactive receptor. Consistent with a previous mutagenesis study<sup><xref rid="R21" ref-type="bibr">21</xref></sup>, the N404Q mutant receptor failed to bind detectable amounts of [<sup>3</sup>H]-NMS, but retained the ability to specifically bind [<sup>3</sup>H]-QNB, although with 163-fold reduced affinity (<xref rid="T2" ref-type="table">Extended Data Table 2</xref>). Similarly, the binding affinities for acetylcholine (ACh) and iperoxo were reduced, and while the N404Q mutant was able to activate G protein in response to both iperoxo and ACh, the concentration-response curves were shifted to the right by about 100-fold (<xref rid="F8" ref-type="fig">Extended Data Fig. 3a</xref>), likely due to the reduced agonist binding affinities. Nevertheless, it remains possible that a structural reorientation of Asn404<sup>6.52</sup> also contributes to M<sub>2</sub> receptor activation.</p>
      <p id="P16">Like Asn404<sup>6.52</sup>, Asp103<sup>3.32</sup> plays a central role in receptor binding to iperoxo, engaging the trimethyl ammonium ion. Cation-Ï interactions with Tyr104<sup>3.33</sup>, Tyr403<sup>6.51</sup> and Tyr426<sup>7.39</sup> form an aromatic lid over the ligand amine (<xref rid="F4" ref-type="fig">Fig. 4f</xref>). To assess the contribution of Asp103<sup>3.32</sup> to receptor activation, we generated and analyzed the D103E mutant M<sub>2</sub> receptor, which abolished agonist-induced M<sub>2</sub> receptor activation (<xref rid="F8" ref-type="fig">Extended Data Fig. 3a</xref>). The D103E mutant receptor bound [<sup>3</sup>H]-NMS with WT-like affinity but showed greatly reduced affinities for ACh (â¼120-fold) and iperoxo (â¼380-fold) (<xref rid="T2" ref-type="table">Extended Data Table 2</xref>), indicating that Asp103<sup>3.32</sup> recognition of the ligand cation plays a critical role in both agonist binding and receptor activation.</p>
      <p id="P17">In the active state of the M<sub>2</sub> receptor, the inward motion of the upper portion of TM6 allows Tyr403<sup>6.51</sup> to hydrogen bond with Tyr104<sup>3.33</sup>, which in turn hydrogen bonds to Tyr426<sup>7.39</sup> (<xref rid="F4" ref-type="fig">Fig. 4f</xref>), resulting in closure of the aforementioned tyrosine lid over the agonist. Hydrogen bonding of this lid appears to be an important feature of agonist binding and activation in muscarinic receptors: mutation of any of the three tyrosines to Phe leads to impaired agonist binding in the homologous M<sub>3</sub> muscarinic receptor<sup><xref rid="R22" ref-type="bibr">22</xref></sup>, and mutation of Tyr104<sup>3.33</sup> and Tyr403<sup>6.51</sup> in the M<sub>2</sub> receptor has a similar effect<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup>. It should be noted that the structure of active M<sub>2</sub> receptor bound to other agonists, including acetylcholine, might show differences as compared to the iperoxo-bound structure presented here.</p>
    </sec>
    <sec id="S5">
      <title>Allosteric modulation</title>
      <p id="P18">Muscarinic receptors have long served as important model systems for understanding allosteric modulation of GPCR signaling<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup>. The structures of the inactive M<sub>2</sub> and M<sub>3</sub> receptors confirmed that these receptors possess a large extracellular vestibule, which has been shown to bind to allosteric modulators<sup><xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup>. Situated directly above (<italic>i.e.</italic>, extracellular to) the orthosteric site, this cavity also shows a substantial contraction upon activation of the M<sub>2</sub> receptor due to the rotation of TM6 (<xref rid="F4" ref-type="fig">Fig. 4b</xref>). The motion of TM6 thus provides a structural link among three regions of the receptor: the extracellular vestibule, the orthosteric binding pocket, and the intracellular surface. The structural coupling of these three regions likely accounts for the fact that allosteric modulators can affect the affinity and efficacy of orthosteric ligands and can also directly activate G proteins as allosteric agonists<sup><xref rid="R28" ref-type="bibr">28</xref></sup>.</p>
      <p id="P19">To better understand how allosteric modulators act at GPCRs, we crystallized the iperoxo-occupied M<sub>2</sub> receptor with LY2119620, a positive allosteric modulator (<xref rid="F5" ref-type="fig">Fig. 5a</xref>). This agent has not been studied previously, so we characterized its affinity for the M<sub>2</sub> receptor and its allosteric interaction with iperoxo (see <xref rid="SD1" ref-type="supplementary-material">Supplementary methods</xref>). Radioligand binding assays revealed that LY2119620 has similar pharmacological properties to its congener, LY2033298<sup><xref rid="R29" ref-type="bibr">29</xref></sup> (<xref rid="F8" ref-type="fig">Extended Data Fig. 3b</xref>; <xref rid="T3" ref-type="table">Extended Data Table 3</xref>). It exhibits strong positive cooperativity with iperoxo, and mild negative cooperativity with the inverse agonist [<sup>3</sup>H]-NMS. While LY2119620 enhances the affinity of the M<sub>2</sub> receptor for iperoxo, it does not significantly change the efficacy of this orthosteric agonist (<xref rid="T3" ref-type="table">Extended Data Table 3</xref>). We also observed that LY2119620 is capable of directly activating the M<sub>2</sub> receptor, albeit with low potency and efficacy relative to iperoxo (<xref rid="T3" ref-type="table">Extended Data Table 3</xref>).</p>
      <p id="P20">Crystals of the M<sub>2</sub> receptor bound to LY2119620 grew under identical conditions to those without the modulator, and the structure revealed unambiguous electron density for LY2119620 in the extracellular vestibule (<xref rid="F10" ref-type="fig">Extended Data Fig. 5</xref>). The modulator is positioned directly above the orthosteric agonist (<xref rid="F5" ref-type="fig">Fig. 5b</xref>), and it engages in extensive interactions with the extracellular vestibule. Specifically, the aromatic rings of the modulator are situated directly between Tyr177<sup>ECL2</sup> and Trp422<sup>7.35</sup>, forming a three-layered aromatic stack. Importantly, a prior mutagenesis study implicated Tyr177<sup>ECL2</sup> as a likely contact for the LY2119620 congener, LY2033298, at the M<sub>2</sub> muscarinic receptor<sup><xref rid="R29" ref-type="bibr">29</xref></sup>. Several polar interactions are also seen (<xref rid="F5" ref-type="fig">Fig. 5c</xref>). In particular, Tyr80<sup>2.61</sup>, Asn410<sup>6.58</sup>, and Asn419<sup>ECL3</sup> form hydrogen bonds to the modulator, and Glu172<sup>ECL2</sup> engages in a charge-charge interaction with the ligand piperidine. LY2119620 binds at a site directly superficial to the orthosteric site, separated only by the tyrosine lid, with Tyr426<sup>7.39</sup> interacting with both ligands.</p>
      <p id="P21">The structure of the M<sub>2</sub>-iperoxo-LY2119620 complex is largely the same as that of receptor and agonist without LY2119620, suggesting that the allosteric binding site is largely pre-formed in the presence of agonist. The extracellular vestibule shows a slight additional contraction around the allosteric ligand (<xref rid="F11" ref-type="fig">Extended Data Fig. 6</xref>). This subtle change stands in contrast to the substantial closure of the extracellular vestibule in the two active structures relative to the inactive conformation (<xref rid="F5" ref-type="fig">Fig. 5d</xref>). A notable exception is Trp422<sup>7.35</sup>, which adopts a vertical conformation in the presence of LY2119620 and a horizontal conformation with iperoxo alone (<xref rid="F11" ref-type="fig">Extended Data Fig. 6b</xref>). The vertical conformation of this residue in the M<sub>2</sub>-iperoxo-LY2119620 complex allows it to engage in an aromatic stacking interaction with the modulator, consistent with mutagenesis results implicating Trp422<sup>7.35</sup> in the binding of other allosteric modulators<sup><xref rid="R30" ref-type="bibr">30</xref></sup>. The effect of mutagenesis of Trp422<sup>7.35</sup> on LY2119620 affinity has not been tested, however. Closure of the LY2119620 binding site in the agonist-bound M<sub>2</sub> receptor allows far more extensive interactions with the modulator than the inverse agonist-bound conformation (<xref rid="F5" ref-type="fig">Fig. 5e</xref>), likely accounting for the ability of the modulator to enhance agonist binding affinity by preferentially slowing agonist dissociation.</p>
      <p id="P22">The closed, active conformation of the extracellular vestibule is largely the consequence of the inward motion of TM6, which directly contacts the allosteric modulator, the orthosteric agonist, and likely the G protein as well. Stabilization of the closed extracellular vestibule by LY2119620 and other allosteric modulators may directly stabilize the open, active conformation of the intracellular side of TM6, accounting for the phenomenon of allosteric agonism in addition to positive cooperativity with orthosteric agonists. However, while the differences in TM6 between inactive and active structures can be described as a rigid-body motion, we cannot exclude the possibility that TM6 is flexible, allowing independent conformational changes in the G-protein binding site, the orthosteric site, and the extracellular vestibule.</p>
    </sec>
    <sec sec-type="conclusions" id="S6">
      <title>Conclusions</title>
      <p id="P23">The structures presented here offer insights into the structural basis for muscarinic receptor activation, and allosteric modulation by a drug-like molecule. In contrast to rhodopsin and the Î²<sub>2</sub>AR, extensive changes are seen in the orthosteric binding site and in the extracellular vestibule upon M<sub>2</sub> receptor activation. The structure of active M<sub>2</sub> receptor bound to the allosteric modulator LY2119620 definitively establishes the extracellular vestibule as an allosteric binding site, and shows that the allosteric modulator induces few additional structural changes as compared to those seen with orthosteric agonist alone. The structures presented here offer only a single view of an active muscarinic receptor; more work will be required to identify additional active states that may exist. Nonetheless, the information presented here provides a structural framework for future studies of GPCR activation and allostery, and may facilitate the development novel therapeutics.</p>
    </sec>
    <sec id="S8" specific-use="web-only">
      <title>Online Methods</title>
      <sec id="S9">
        <title>Determination of M<sub>2</sub> activation via inositol phosphate (IP) assays</title>
        <p id="P25">Agonist-induced activation of the human M<sub>2</sub> muscarinic receptor was studied in IP accumulation assays as described<sup><xref rid="R31" ref-type="bibr">31</xref></sup>. For M<sub>2</sub> activation studies, HEK 293 cells were transiently cotransfected with cDNAs encoding the human M<sub>2</sub> receptor (Missouri S&amp;T cDNA Resource Center, Rolla, MO) and the hybrid G-protein GÎ±<sub>qi5</sub> (GÎ±<sub>q</sub> protein with the last five amino acids at the C-terminus replaced by the corresponding sequence of GÎ±<sub>i</sub>; gift from <italic>The J. David Gladstone Institutes</italic>, San Francisco, CA)<sup><xref rid="R32" ref-type="bibr">32</xref></sup>. Twenty-four hours after transfection, cells were transferred into 24 well plates at a density of 100,000 cells per well in a volume of 270 Î¼L. After addition of 30 Î¼L of <italic>myo</italic>-[<sup>3</sup>H]inositol (specific activity = 22.5 Ci/mmol, PerkinElmer, Rodgau, Germany), cells were incubated for 15 hrs. Then, medium was aspirated, the cells were washed with serum-free medium supplemented with 10 mM LiCl, and test compounds (diluted in serum-free medium supplemented with 10 mM LiCl) were added at 37 Â°C for 60 min. Cells were then lysed by adding 150 Î¼L of ice-cold 0.1 M NaOH for 5 min. After neutralisation with 50 Î¼l of 0.2 M formic acid, the cell extract was diluted in buffer (5 mM sodium tetraborate, 0.5 mM Na-EDTA) and separated by anion-exchange chromatography using an AG1-X8 resin (Bio-Rad, Munich, Germany). After washing with water and elution-buffer A (5 mM sodium tetraborate, 60 mM sodium formate) and again with water, total IP was eluted with 2.5 mL elution-buffer B (1.0 M ammonium formate) and directly collected into scintillation counting vials. Radioactivity was measured by scintillation counting after adding 2.5 ml of Emulsifier-Safe (PerkinElmer, Rodgau, Germany). Data were analysed by normalizing dpm values with 0% for the non-stimulated receptor and 100% for the full effect of the reference iperoxo. Dose-response curves were calculated by non-linear regression using the Graphpad Prism 5 software.</p>
        <p id="P26">Irreversible activation of the M<sub>2</sub> receptor was tested at 1 nM FAUC123 in comparison to the reversible ligand iperoxo (1 nM). After incubation for 30 min, the antagonist atropine (1 Î¼M) was added to one half of the sample (buffer was added to the other half) and incubations were continued for an additional 90 min. Total IP accumulation was determined as described above.</p>
      </sec>
      <sec id="S10">
        <title>LY2119620 pharmacology</title>
        <p id="P27">To characterize the allosteric interaction between LY2119620 and iperoxo, we performed radioligand binding and cellular functional assays at the wild-type human M<sub>2</sub> muscarinic receptor stably expressed in a CHO FlpIn cell line. Increasing concentrations of LY2119620 caused a modest reduction in the specific binding of the orthosteric antagonist, [<sup>3</sup>H]-NMS, indicating weak negative cooperativity, but robustly enhanced the potency of iperoxo to compete for [<sup>3</sup>H]-NMS binding, indicating positive cooperativity with the agonist (<xref rid="F8" ref-type="fig">Extended Data Fig. 3b</xref>). Application of an allosteric ternary complex model<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> to these data yielded the values shown in <xref rid="T3" ref-type="table">Extended Data Table 3</xref> for ligand affinity and cooperativities with agonist and antagonist. We then investigated the functional effect of LY2119620 on M<sub>2</sub> muscarinic receptor signaling via monitoring receptor-mediated [<sup>35</sup>S]-GTPÎ³S binding to activated G proteins, or phosphorylation of ERK1/2. [<sup>35</sup>S]-GTPÎ³S binding was chosen as a proximal measure of receptor activation, while the pERK1/2 assay was chosen because it measures a downstream response that is also a point of convergence of multiple cellular pathways, some of them potentially G protein-independent. In both instances, LY2119620 caused receptor activation in its own right, indicating that the modulator can act as an allosteric agonist, while simultaneously enhancing the potency of iperoxo (<xref rid="F8" ref-type="fig">Extended Data Fig. 3b</xref>). Application of an operational model of allosterism<sup><xref rid="R35" ref-type="bibr">35</xref></sup> to these data yielded the parameter values shown in <xref rid="T3" ref-type="table">Extended Data Table 3</xref>. Comparison of the binding and functional data indicated that there was no significant difference between any of the pK<sub>B</sub> estimates of the affinity of LY2119620 for the allosteric site on the free receptor between assays. There was also no significant difference between the cooperativity factors with iperoxo across the assays, indicating that the molecular mechanism of action of LY2119620 is consistent with positive modulation of agonist affinity only, with minimal additional effects on agonist efficacy. This is in contrast to the more complex behavior previously noted with the congener, LY2033298, at the M<sub>2</sub> receptor<sup><xref rid="R29" ref-type="bibr">29</xref></sup>. Full methods details are available in the <xref rid="SD1" ref-type="supplementary-material">Supplementary Methods</xref>.</p>
      </sec>
      <sec id="S11">
        <title>M<sub>2</sub> muscarinic receptor expression and purification</title>
        <p id="P28">The human M<sub>2</sub> muscarinic receptor gene was modified to remove glycosylation sites, and to add an amino-terminal FLAG epitope tag and a carboxy-terminal 8ÃHis tag. In addition, residues 233 â 374 of intracellular loop 3 were deleted. This region has previously been shown to be unstructured<sup><xref rid="R36" ref-type="bibr">36</xref></sup> and is not essential for G protein coupling in the homologous M<sub>1</sub> muscarinic receptor<sup><xref rid="R37" ref-type="bibr">37</xref></sup>. This construct was expressed in <italic>Sf9</italic> insect cells using the BestBac baculovirus system (Expression Systems; Davis, CA). Cells were infected at a density of 4 Ã 10<sup>6</sup> cells/mL and then incubated for two days at 27 Â°C. Receptor was extracted and purified in the manner described previously for the M<sub>3</sub> muscarinic receptor<sup><xref rid="R8" ref-type="bibr">8</xref></sup>. Briefly, receptor was purified by Ni-NTA chromatography, FLAG affinity chromatography and size exclusion chromatography.</p>
      </sec>
      <sec id="S12">
        <title>Llama immunization samples</title>
        <p id="P29">M<sub>2</sub> receptor was prepared as described above, and bound to iperoxo by including it at 10 Î¼M starting at FLAG wash steps and in all subsequent buffers. Receptor was reconstituted into phospholipid vesicles composed of DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids) and Lipid A in a 10:1 (w:w) ratio, then aliquoted at 1 mg/mL receptor concentration and frozen in 100 Î¼L aliquots prior to injection.</p>
      </sec>
      <sec id="S13">
        <title>Yeast display samples</title>
        <p id="P30">M<sub>2</sub> receptor was purified as described above with 1 Î¼M atropine included in all buffers. Receptor was then labeled with a 5-fold molar excess of biotin-NHS ester (Sigma-Aldrich; St. Louis, MO) in buffer containing 25 mM HEPES pH 7.2. Following a 30 min incubation at room temperature and a 30 min incubation on ice, unreacted label was quenched with 50 mM tris pH 8. Directly labeled samples with fluorophore-NHS esters were prepared in a similar manner. Receptor was then desalted into buffer containing either 10 Î¼M tiotropium, 10 Î¼M iperoxo, or buffer containing no ligand. Receptor eluted in buffer containing no ligand was treated with 50 Î¼M iperoxo mustard (FAUC123; see <xref rid="SD1" ref-type="supplementary-material">Supplementary Information</xref> for details) for 20 min at room temperature. Samples were then concentrated, aliquoted, and flash frozen with 20% (v/v) glycerol.</p>
      </sec>
      <sec id="S14">
        <title>Crystallization samples</title>
        <p id="P31">M<sub>2</sub> receptor for crystallization was prepared as described above. When bound to FLAG resin, the sample was washed with a mix of dodecyl maltoside buffer (DDM) and buffer containing 0.2% lauryl maltose neopentyl glycol detergent (MNG; Anatrace). These buffers were mixed first in a 1:1 ratio (DDM:MNG buffer), then 1:4, and 1:10 ratios. At each step the 5 mL column was washed with 10 mL of buffer at a 1 mL/min flow rate, and all buffers contained 1 Î¼M atropine. Finally, the column was washed with 10 mL MNG buffer, and then 10 mL of low detergent buffer with agonist (0.01% MNG, 0.001% cholesterol hemisuccinate, 20 mM HEPES pH 7.5, 100 mM NaCl, 10 Î¼M iperoxo). The sample was eluted, mixed with a 1.5-fold stoichiometric excess of Nb9-8 and a second nanobody, NbB4. This nanobody binds to an epitope different from Nb9-8, but was not resolved in the crystal structure. Following mixing, the sample was incubated 30 min on ice, then concentrated and purified by size exclusion in low detergent buffer. Eluted protein was concentrated to A<sub>280</sub> = 96, and frozen in liquid nitrogen in 7 Î¼L aliquots.</p>
      </sec>
      <sec id="S15">
        <title>Llama immunization</title>
        <p id="P32">One Llama (<italic>Lama glama</italic>) was immunized for six weeks with 1 mg receptor in total. Peripheral blood lymphocytes were isolated from the immunized animal to extract total RNA. cDNA was prepared using 50 Î¼g of total RNA and 2.5 Î¼g of oligo-dN6primer. Nanobody open reading frames were amplified as described<sup><xref rid="R38" ref-type="bibr">38</xref></sup>.</p>
      </sec>
      <sec id="S16">
        <title>Post-immune M<sub>2</sub> receptor llama nanobody library construction</title>
        <p id="P33">Nanobody V<sub>HH</sub> fragments were amplified by PCR using the primers pYalNB80AMPF (CATTTTCAAT TAAGATGCAG TTACTTCGCT GTTTTTCAAT ATTTTCTGTT ATTGCTAGCG TTTTAGCAAT GGCCCAGGTG CAGCTGCAGG AG) and pYalNB80AMPR (CCACCAGATC CACCACCACC CAAGTCTTCT TCGGAGATAA GCTTTTGTTC GGATCCTGAG GAGACGGTGA CCTGGGTCCC). The PCR products were then co-transformed with linearized pYal into yeast strain EBY100 as for the Nb80 affinity-maturation library, yielding a library size of 0.6Ã10<sup>8</sup> transformants.</p>
      </sec>
      <sec id="S17">
        <title>Selection of M<sub>2</sub> G<sub>i</sub>-mimetic nanobodies from post-immune M<sub>2</sub> llama nanobody library</title>
        <p id="P34">For the first round of selection, counter-selection was performed against the Î²<sub>2</sub> receptor to remove yeast clones that bind non-specifically to membrane proteins or to secondary staining reagents. 1.0Ã10<sup>9</sup> of induced yeast were washed with PBEM buffer and then stained in 5 mL of PBEM buffer containing 1 Î¼M biotinylated Î²<sub>2</sub> receptor liganded with carazolol for 1 hr at 4 Â°C. Yeast were then stained with streptavidin-647 as a secondary reagent and magnetically-labeled with anti-647 microbeads (Miltenyi) as described previously<sup><xref rid="R18" ref-type="bibr">18</xref></sup>. Positively-labeled yeast were then removed by the use of an LD column (Miltenyi); the cleared flow-through was then used for subsequent selection. Positive selection for clones recognizing the active state of the M<sub>2</sub> receptor was performed by staining with 2 Î¼M biotinylated M<sub>2</sub> receptor bound to the agonist iperoxo in 5 mL PBEM buffer supplemented with 2 Î¼M iperoxo for 1 hr at 4Â°C. Yeast were then washed, stained with streptavidin-647, and magnetically-labeled with anti-647 microbeads, including 1 Î¼M iperoxo in the PBEM buffer at all steps. Magnetic separation of M<sub>2</sub> receptor-binding yeast clones was performed using an LS column (Miltenyi) following the manufacturer's instructions. Magnetically sorted yeast were resuspended in SDCAA medium and cultured at 30Â°C. Rounds 2-4 were selected in a similar manner, counter-selecting against 1 Î¼M biotinylated Î²<sub>2</sub> receptor bound to carazolol and positively selecting using 1 Î¼M biotinylated M<sub>2</sub> receptor bound to iperoxo. For these rounds, the scale was reduced ten-fold to 1 Ã 10<sup>8</sup> induced yeast and staining volumes of 0.5 mL.</p>
        <p id="P35">Conformational selection was performed for rounds 5-9. For rounds 5-8, yeast were stained with 1 Î¼M biotinylated M<sub>2</sub> receptor pre-incubated with the high-affinity antagonist tiotropium for 1 hr at 4Â°C. Yeast were then fluorescently labeled with either streptavidin-647 or streptavidin-PE, and magnetically labeled with the corresponding anti-647 or anti-PE microbeads (Miltenyi). Depletion of inactive-state binders was carried out using an LS column. The cleared yeast were then positively selected by staining with 0.5 Î¼M (rounds 5-7) or 0.1 Î¼M (round 8) M<sub>2</sub> receptor pre-bound to iperoxo for 1 hr at 4Â° C. Yeast were then fluorescently-labeled with either streptavidin-PE or streptavidin-647, using a fluorophore distinct from that used in the previous counter-selection step. Magnetic separation of agonist-occupied M<sub>2</sub> receptor was performed using an LS column, as for steps 1-4. For round 9, two-color FACS was performed. Induced yeast were simultaneously stained with 1 Î¼M Alexa647-labeled M<sub>2</sub> receptor reacted with iperoxo mustard and 1 Î¼M Alexa488-labeled M<sub>2</sub> receptor pre-bound with tiotropium for 1 hr at 4Â°C. Alexa647 positive/Alexa488 negative yeast were purified using a FACS Jazz cell (BD Biosciences) sorter. Post-sorted yeast were plated onto SDCAA-agar plates and the nanobody-encoding sequences of several colonies were sequenced. Full sequences of clones confirmed to enhance agonist affinity are below:</p>
        <array orientation="portrait">
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Clone</bold>
              </td>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <bold>Full amino acid sequence</bold>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Nb9-1</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<monospace>QVQLQESGGG LVQAGGSLRL SCAASGHTFS SARMYWVRQA PGKEREFVAA ISRSGFTYSA DSVKGRFTIS RDIANNTVYL QMNSLQPEDT AIYTCYAAYL DEFYNDYTHY WGLGTQVTVS S</monospace></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Nb9-8</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<monospace>QVQLQESGGG LVQAGDSLRL SCAASGFDFD NFDDYAIGWF RQAPGQEREG VSCIDPSDGS TIYADSAKGR FTISSDNAEN TVYLQMNSLK PEDTAVYVCS AWTLFHSDEY WGQGTQVTVS S</monospace></td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">Nb9-20</td>
              <td align="left" valign="top" rowspan="1" colspan="1">
<monospace>QVQLQESGGG LVQPEGSLTL ACDTSGFTMN YYAIAWFRQA PEKEREGLAT ISSIDGRTYY ADSVKGRFTI SRDSAKNMVY LQMNNLRPED TAVYYCSAGP DYSDYGDESE YWGQGTQVTV SS</monospace></td>
            </tr>
          </tbody>
        </array>
      </sec>
      <sec id="S18">
        <title>Expression of MBP-nanobody fusions in <italic>E. coli</italic></title>
        <p id="P36">Nanobody sequences were subcloned into a modified pMalp2x vector (New England Biolabs), containing an amino-terminal, 3C protease-cleavable maltose binding protein (MBP) tag and a carboxy-terminal 8ÃHis tag. Plasmids were transformed into BL21(DE3) cells and protein expression induced in Terrific Broth by addition of IPTG to 1 mM at an OD<sub>600</sub> of 0.8. After 24 hr of incubation at 22Â°C, cells were harvested and periplasmic protein was obtained by osmotic shock. MBP-nanobody fusions were purified by Ni-NTA chromatography and MBP was removed using 3C protease. Cleaved MBP was separated from the 8ÃHis tagged nanobodies by an additional Ni-NTA purification step. The 8ÃHis tag was subsequently removed using carboxypeptidase A.</p>
      </sec>
      <sec id="S19">
        <title>Expression and purification of G protein</title>
        <p id="P37">Heterotrimeric G<sub>i</sub> was prepared by expression using a single baculovirus for the human GÎ±<sub>i1</sub> subunit and a second, bicistronic virus for human GÎ²1 and GÎ³2 subunits. G protein was expressed in HighFive insect cells, and then purified as described previously for G<sub>s</sub><sup>10</sup>. In brief, G protein was extracted with cholate, purified by Ni-NTA chromatography, detergent exchanged into dodecyl maltoside buffer, and then purified by ion exchange and dialyzed prior to use.</p>
      </sec>
      <sec id="S20">
        <title>M<sub>2</sub> receptor radioligand binding assays with G protein and nanobody</title>
        <p id="P38">M<sub>2</sub> receptor was expressed and purified as described above. Receptor was then reconstituted into HDL particles consisting of apolipoprotein A1 and a 3:2 (mol:mol) mixture of the lipids POPC:POPG (1- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine: 1- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1â²-rac-glycerol) respectively, Avanti Polar Lipids). Binding reactions contained 50 fmol functional receptor, 0.6 nM [<sup>3</sup>H] N-methyl scopolamine (NMS), 100 mM NaCl, 20 mM HEPES pH 7.5, 0.1% BSA, and ligands and nanobodies as indicated. Concentration-dependent effects of nanobodies were measured in the presence of 10 nM iperoxo. All reactions were carried out in a 500 Î¼L volume. For samples containing G protein, purified G<sub>i</sub> heterotrimer from insect cells was added to the reactions at a 1000-fold dilution from a 200 Î¼M stock, resulting in a large stoichiometric excess over receptor and diluting G protein below the detergent CMC to allow incorporation into HDL particles, essentially as described previously<sup><xref rid="R39" ref-type="bibr">39</xref></sup>. Reactions were mixed and then incubated for 2 hr. Samples were then filtered on a 48-well harvester (Brandel) onto a filter which had been pre-treated with 0.1% polyethylenimine. All measurements were taken by liquid scintillation counting, and experiments were performed at least in triplicate.</p>
      </sec>
      <sec id="S21">
        <title>Site-directed mutagenesis</title>
        <p id="P39">A mammalian expression plasmid coding for the human M<sub>2</sub> muscarinic receptor (M<sub>2</sub>R-pcDNA3.1+) was obtained from the Missouri S&amp;T cDNA Resource Center. Mutant M<sub>2</sub> receptors were generated by using the QuikChange site-directed mutagenesis kit (Stratagene, Foster City, CA, USA) according to the manufacturer's instructions. The identity of all mutant M<sub>2</sub> receptor constructs was confirmed by DNA sequencing.</p>
      </sec>
      <sec id="S22">
        <title>Transient expression of receptor constructs in COS-7 cells</title>
        <p id="P40">WT and mutant M<sub>2</sub> receptors were transiently expressed in COS-7 cells grown in 100 mm dishes, as described previously<sup><xref rid="R40" ref-type="bibr">40</xref></sup>. For functional studies, the various receptor constructs (3 Î¼g each) were co-expressed with a chimeric G protein Î± subunit (G<sub>qi5</sub>; 3 Î¼g plasmid DNA) in which the last five amino acids of GÎ±<sub>q</sub> were replaced with the corresponding GÎ±<sub>i</sub> sequence<sup><xref rid="R41" ref-type="bibr">41</xref></sup>.</p>
      </sec>
      <sec id="S23">
        <title>Radioligand binding studies of mutant and WT M<sub>2</sub> receptors</title>
        <p id="P41">Acetylcholine (ACh) bromide was purchased from Sigma (St. Louis, MO, USA). Iperoxo was a generous gift of Bristol Myers Squibb (New York, NY). [<sup>3</sup>H]-NMS (85.5 Ci/mmol) and 3-quinuclidinyl benzilate ([<sup>3</sup>H]-QNB; 47.4 Ci/mmol) were from PerkinElmer Life Sciences (Downers Grove, IL, USA). Radioligand binding studies were carried out with membranes prepared from transfected COS-7 cells as described<sup><xref rid="R41" ref-type="bibr">41</xref></sup>. Forty-eight hours after transfection, cells were harvested and resuspended in 25 mM sodium phosphate buffer (pH 7.4) containing 5 mM MgCl<sub>2</sub>. Membrane homogenates were prepared and resuspended in the same buffer. [<sup>3</sup>H]-NMS or [<sup>3</sup>H]-QNB binding reactions were carried out in the presence of 9 Î¼g of membrane protein for 3 hr at room temperature (total volume of the incubation mixture: 0.5 ml). In saturation binding studies, six different concentrations of the radioligand were used ([<sup>3</sup>H]-NMS, 0.3 nM to 10 nM; [<sup>3</sup>H]-QNB, 0.05 nM to 20 nM). In competition binding assays, membrane homogenates were incubated with ten different concentrations of ACh (13 nM to 1 mM) or iperoxo (0.13 nM to 10 Î¼M) in the presence of a fixed concentration of radioligand (2 nM [<sup>3</sup>H]-NMS for all receptors except N404Q; 15 nM [<sup>3</sup>H]-QNB for N404Q and 0.5 nM [<sup>3</sup>H]-QNB for WT M<sub>2</sub> receptor). Non-specific binding was determined in the presence of 10 Î¼M atropine. Reactions were stopped by rapid filtration through GF/C filters. Data were analyzed using Prism 4.0 software (GraphPad Software, Inc., San Diego, CA).</p>
      </sec>
      <sec id="S24">
        <title>Calcium mobilization assay</title>
        <p id="P42">COS-7 cells co-expressing WT or mutant M<sub>2</sub> receptor and the hybrid G protein, G<sub>qi5</sub><sup>41</sup>, were incubated with increasing concentrations of agonists (ACh, 5 nM to 50 Î¼M; iperoxo, 50 pM to 0.5 Î¼M), and increases in intracellular calcium levels were determined in 96-well plates using FLIPR technology (Molecular Devices, Sunnyvale, CA), as described in detail previously<sup><xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup>. Agonist concentration-response curves were analyzed using Prism 4.0 software.</p>
      </sec>
      <sec id="S25">
        <title>Crystallization</title>
        <p id="P43">Purified M<sub>2</sub> receptor was reconstituted into lipidic cubic phase by mixing with a 1.5-fold excess by mass of 10:1 (w:w) monoolein cholesterol lipid mix. Protein and lipid were loaded into glass syringes (Art Robbins Instruments, Sunnyvale, CA), and then mixed 100 times by the coupled syringe method<sup><xref rid="R44" ref-type="bibr">44</xref></sup>. Samples of 30 â 100 nL in volume were spotted onto 96 well glass plates and overlaid <italic>en bloc</italic> with 600 nL precipitant solution for each well. Precipitant solution consisted of 10 â 20% PEG300, 100 mM HEPES pH 7.2 â 7.9, 1.2% 1,2,3-heptanetriol, and 20 â 80 mM EDTA pH 8.0. Identical conditions were used to crystallize LY2119620-receptor complexes, except that the overlay precipitant solution was supplemented with 500 Î¼M LY2119620. Crystals grew in 24 hr, and reached full size within two days. Crystals were then harvested in mesh grid loops (MiTeGen, Ithaca, NY) with 10 â 50 crystals per loop and stored in liquid nitrogen prior to use.</p>
      </sec>
      <sec id="S26">
        <title>Data collection</title>
        <p id="P44">Grids of crystals were rastered at Advanced Photon Source beamlines 23ID-B and 23ID-D. Initial rastering was performed with an 80 Î¼m by 30 Î¼m beam with 5-fold attenuation and 1 sec exposure, and regions with strong diffraction were sub-rastered with a 10 Î¼m collimated beam with equivalent X-ray dose. Data collection was similarly performed with a 10 Î¼m beam, but with no attenuation and exposures of typically 1 â 5 s. An oscillation width of 1 â 2 degrees was used in each case, and wedges of 5 â 10 degrees were compiled to create the final data sets.</p>
      </sec>
      <sec id="S27">
        <title>Data reduction and refinement</title>
        <p id="P45">Diffraction data were processed in <italic>HKL2000</italic><sup><xref rid="R45" ref-type="bibr">45</xref></sup>, and statistics are summarized in <xref rid="T1" ref-type="table">Extended Data Table 1</xref>. The structure was solved using molecular replacement with the structure of the inactive M<sub>2</sub> receptor (PDB ID: 3UON) and Nb80 (PDB ID: 3P0G) as search models in <italic>Phaser</italic><sup><xref rid="R46" ref-type="bibr">46</xref></sup>. The resulting structure was iteratively refined in <italic>Phenix</italic><sup><xref rid="R47" ref-type="bibr">47</xref></sup> and manually rebuilt in <italic>Coot</italic><sup><xref rid="R48" ref-type="bibr">48</xref></sup>. Final refinement statistics are summarized in <xref rid="T1" ref-type="table">Extended Data Table 1</xref>. Figures were prepared in <italic>PyMol</italic> (SchrÃ¶dinger).</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="S28">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>1</label>
        <media xlink:href="NIHMS529325-supplement-1.pdf" orientation="portrait" xlink:type="simple" id="d37e1498" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S29">
      <p>We acknowledge support from the National Science Foundation (graduate fellowship to A.C.K., and Award 1223785 to B.K.K) , the Stanford Medical Scientist Training Program (A.M. and A.M.R.), the American Heart Association (A.M.), the Ruth L. Kirschstein National Research Service Award (A.M.R.), National Institutes of Health grants NS02847123 and GM08311806 (B.K.K.), the Mathers Foundation (B.K.K., W.I.W., and K.C.G), the Deutsche Forschungsgemeinschaft for the grant GM 13/10-1 (K.E., H.H., P.G.), the National Health and Medical Research Council (NHMRC) of Australia program grant 519461 (P.M.S. and A.C.), NHMRC Principal Research Fellowships (P.M.S. and A.C.), and the Howard Hughes Medical Institute (K.C.G.). This work was supported in part by the Intramural Research Program, NIDDK, NIH, US Department of Health and Human Services (J.H., K.H., and J.W.). We thank Katie Leach for performing ERK assays, Briana Davie and Peter Scammells for synthesis of iperoxo. We thank Hongling Xiao, Carrie H. Croy, Douglas A. Schober for functional characterization of LY2119620. We thank Tong Sun Kobilka for preparation of affinity chromatography reagents and Foon Sun Thian for help with cell culture.</p>
    </ack>
    <fn-group>
      <fn id="FN3">
        <p><bold>Full Methods</bold> and associated references are available in the online version of the paper at <ext-link ext-link-type="uri" xlink:href="www.nature.com/nature">www.nature.com/nature</ext-link>.</p>
      </fn>
      <fn id="FN4" fn-type="supplementary-material">
        <p><bold><xref rid="SD1" ref-type="supplementary-material">Supplementary Information</xref></bold> is linked to the online version of the paper at <ext-link ext-link-type="uri" xlink:href="www.nature.com/nature">www.nature.com/nature</ext-link>.</p>
      </fn>
      <fn id="FN5" fn-type="con">
        <p><bold>Author Contributions</bold>: A.C.K. expressed and purified M<sub>2</sub> receptor for yeast display and crystallographic experiments, performed crystallization, data collection, and structure refinement, and performed radioligand binding assays to validate nanobody activity. A.C.K. A.M.R. and A.M. designed experiments to identify nanobodies by yeast display. A.M.R. performed all yeast selections, and expressed and purified Nb9-8 and other nanobodies. J.H. and K.H. performed site-directed mutagenesis and characterization of resulting mutants. K.E. synthesized FAUC123. H.H. performed cell assays and radioligand binding to characterize FAUC123. C.V. performed pharmacological characterization of LY2119620. P.M.S. and A.C. supervised pharmacological characterization of LY2119620. C.C.F. designed key solubility, physical chemistry and ligand analysis to select LY2119620 as an appropriate co-crystallization candidate for the M<sub>2</sub> receptor. P.G. supervised synthesis and characterization of FAUC123. E.P. and J.S. performed llama immunization, cDNA production, and performed selections by phage display. W.I.W. supervised structure refinement. K.C.G. supervised yeast selection experiments. J.W. supervised mutagenesis experiments and analyzed results. B.K.K. provided overall project supervision, and with A.C.K., A.M.R., and A.M. wrote the manuscript with assistance from A.C. and J.W.</p>
      </fn>
      <fn id="FN6">
        <p><bold>Author Information</bold>: Coordinates and structure factors for the active M<sub>2</sub> receptor in complex with Nb9-8 and iperoxo are deposited in the Protein Data Bank under accession code 4MQS, and the coordinates and structure factors of the same complex bound additionally to the allosteric modulator LY2119620 are deposited under accession code 4MQT.</p>
      </fn>
      <fn id="FN7">
        <p>Reprints and permission information is available at <ext-link ext-link-type="uri" xlink:href="www.nature.com/reprints">www.nature.com/reprints</ext-link>. Readers are welcome to comment on the online version of this article at <ext-link ext-link-type="uri" xlink:href="www.nature.com/nature">www.nature.com/nature</ext-link>.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wess</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Eglen</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Gautam</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development</article-title>
          <source>Nat Rev Drug Discov</source>
          <volume>6</volume>
          <fpage>721</fpage>
          <lpage>733</lpage>
          <year>2007</year>
          <pub-id pub-id-type="pmid">17762886</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peterson</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Herron</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Yamaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fullerton</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Schimerlik</surname>
              <given-names>MI</given-names>
            </name>
          </person-group>
          <article-title>Purification of the muscarinic acetylcholine receptor from porcine atria</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>81</volume>
          <fpage>4993</fpage>
          <lpage>4997</lpage>
          <year>1984</year>
          <pub-id pub-id-type="pmid">6589642</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kubo</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence</article-title>
          <source>FEBS Lett</source>
          <volume>209</volume>
          <fpage>367</fpage>
          <lpage>372</lpage>
          <year>1986</year>
          <pub-id pub-id-type="pmid">3792556</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohr</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Trankle</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Holzgrabe</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Structure/activity relationships of M2 muscarinic allosteric modulators</article-title>
          <source>Receptors Channels</source>
          <volume>9</volume>
          <fpage>229</fpage>
          <lpage>240</lpage>
          <year>2003</year>
          <pub-id pub-id-type="pmid">12893536</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Digby</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Shirey</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Conn</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders</article-title>
          <source>Mol Biosyst</source>
          <volume>6</volume>
          <fpage>1345</fpage>
          <lpage>1354</lpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20582339</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keov</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sexton</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Christopoulos</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Allosteric modulation of G protein-coupled receptors: a pharmacological perspective</article-title>
          <source>Neuropharmacology</source>
          <volume>60</volume>
          <fpage>24</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuropharm.2010.07.010</pub-id>
          <year>2011</year>
          <pub-id pub-id-type="pmid">20637785</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haga</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist</article-title>
          <source>Nature</source>
          <volume>482</volume>
          <fpage>547</fpage>
          <lpage>551</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22278061</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kruse</surname>
              <given-names>AC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure and dynamics of the M3 muscarinic acetylcholine receptor</article-title>
          <source>Nature</source>
          <volume>482</volume>
          <fpage>552</fpage>
          <lpage>556</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22358844</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choe</surname>
              <given-names>HW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Crystal structure of metarhodopsin II</article-title>
          <source>Nature</source>
          <volume>471</volume>
          <fpage>651</fpage>
          <lpage>655</lpage>
          <year>2011</year>
          <pub-id pub-id-type="pmid">21389988</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rasmussen</surname>
              <given-names>SG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Crystal structure of the beta2 adrenergic receptor-Gs protein complex</article-title>
          <source>Nature</source>
          <volume>477</volume>
          <fpage>549</fpage>
          <lpage>555</lpage>
          <year>2011</year>
          <pub-id pub-id-type="pmid">21772288</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rasmussen</surname>
              <given-names>SG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor</article-title>
          <source>Nature</source>
          <volume>469</volume>
          <fpage>175</fpage>
          <lpage>180</lpage>
          <year>2011</year>
          <pub-id pub-id-type="pmid">21228869</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deupi</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stabilized G protein binding site in the structure of constitutively active metarhodopsin-II</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>109</volume>
          <fpage>119</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1114089108</pub-id>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22198838</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scheerer</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Crystal structure of opsin in its G-protein-interacting conformation</article-title>
          <source>Nature</source>
          <volume>455</volume>
          <fpage>497</fpage>
          <lpage>502</lpage>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18818650</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nygaard</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The dynamic process of beta(2)-adrenergic receptor activation</article-title>
          <source>Cell</source>
          <volume>152</volume>
          <fpage>532</fpage>
          <lpage>542</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">23374348</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kloeckner</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schmitz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Holzgrabe</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Convergent, short synthesis of the muscarinic superagonist iperoxo</article-title>
          <source>Tetrahedron Lett</source>
          <volume>51</volume>
          <fpage>3470</fpage>
          <lpage>3472</lpage>
          <year>2010</year>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hudgins</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Stubbins</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>A comparison of the action of acetylcholine and acetylcholine mustard (chloroethylmethylaminoethyl acetate) on muscarinic and nicotinic receptors</article-title>
          <source>J Pharmacol Exp Ther</source>
          <volume>182</volume>
          <fpage>303</fpage>
          <lpage>311</lpage>
          <year>1972</year>
          <pub-id pub-id-type="pmid">4538023</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spalding</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Birdsall</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Hulme</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <article-title>Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors</article-title>
          <source>J Biol Chem</source>
          <volume>269</volume>
          <fpage>4092</fpage>
          <lpage>4097</lpage>
          <year>1994</year>
          <pub-id pub-id-type="pmid">8307968</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ring</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adrenaline-activated structure of the Î²2-adrenoceptor stabilized by an engineered nanobody</article-title>
          <source>Nature</source>
          <pub-id pub-id-type="doi">10.1038/nature12572</pub-id>
          <year>2013</year>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Gasper</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Metzger</surname>
              <given-names>VT</given-names>
            </name>
            <name>
              <surname>McCammon</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Activation and dynamic network of the M2 muscarinic receptor</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>110</volume>
          <fpage>10982</fpage>
          <lpage>10987</lpage>
          <year>2013</year>
          <pub-id pub-id-type="pmid">23781107</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ballesteros</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6</article-title>
          <source>J Biol Chem</source>
          <volume>276</volume>
          <fpage>29171</fpage>
          <lpage>29177</lpage>
          <year>2001</year>
          <pub-id pub-id-type="pmid">11375997</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heitz</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site</article-title>
          <source>Eur J Pharmacol</source>
          <volume>380</volume>
          <fpage>183</fpage>
          <lpage>195</lpage>
          <year>1999</year>
          <pub-id pub-id-type="pmid">10513578</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wess</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maggio</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants</article-title>
          <source>J Biol Chem</source>
          <volume>267</volume>
          <fpage>19313</fpage>
          <lpage>19319</lpage>
          <year>1992</year>
          <pub-id pub-id-type="pmid">1527051</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vogel</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Sheehan</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Schimerlik</surname>
              <given-names>MI</given-names>
            </name>
          </person-group>
          <article-title>Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: the significance of Tyr403 in the binding of agonists and functional coupling</article-title>
          <source>Mol Pharmacol</source>
          <volume>52</volume>
          <fpage>1087</fpage>
          <lpage>1094</lpage>
          <year>1997</year>
          <pub-id pub-id-type="pmid">9415719</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gregory</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Tobin</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Sexton</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Christopoulos</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias</article-title>
          <source>J Biol Chem</source>
          <volume>285</volume>
          <fpage>7459</fpage>
          <lpage>7474</lpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20051519</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Amici</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dallanoce</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Holzgrabe</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Trankle</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mohr</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities</article-title>
          <source>Med Res Rev</source>
          <volume>30</volume>
          <fpage>463</fpage>
          <lpage>549</lpage>
          <year>2010</year>
          <pub-id pub-id-type="pmid">19557759</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gregory</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Sexton</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Christopoulos</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Allosteric modulation of muscarinic acetylcholine receptors</article-title>
          <source>Curr Neuropharmacol</source>
          <volume>5</volume>
          <fpage>157</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="doi">10.2174/157015907781695946</pub-id>
          <year>2007</year>
          <pub-id pub-id-type="pmid">19305798</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bock</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling</article-title>
          <source>Nat Commun</source>
          <volume>3</volume>
          <fpage>1044</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms2028</pub-id>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22948826</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>May</surname>
              <given-names>LT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors</article-title>
          <source>Mol Pharmacol</source>
          <volume>72</volume>
          <fpage>463</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="doi">10.1124/mol.107.037630</pub-id>
          <year>2007</year>
          <pub-id pub-id-type="pmid">17525129</pub-id>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valant</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Felder</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Sexton</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Christopoulos</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects</article-title>
          <source>Mol Pharmacol</source>
          <volume>81</volume>
          <fpage>41</fpage>
          <lpage>52</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">21989256</pub-id>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prilla</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schrobang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Holtje</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Mohr</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity</article-title>
          <source>Mol Pharmacol</source>
          <volume>70</volume>
          <fpage>181</fpage>
          <lpage>193</lpage>
          <year>2006</year>
          <pub-id pub-id-type="pmid">16641315</pub-id>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chee</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The third intracellular loop stabilizes the inactive state of the neuropeptide Y1 receptor</article-title>
          <source>J Biol Chem</source>
          <volume>283</volume>
          <fpage>33337</fpage>
          <lpage>33346</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M804671200</pub-id>
          <year>2008</year>
          <pub-id pub-id-type="pmid">18812316</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Broach</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Thorner</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>High-throughput screening for drug discovery</article-title>
          <source>Nature</source>
          <volume>384</volume>
          <fpage>14</fpage>
          <lpage>16</lpage>
          <year>1996</year>
          <pub-id pub-id-type="pmid">8895594</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ehlert</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
          <article-title>Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods</article-title>
          <source>Mol Pharmacol</source>
          <volume>33</volume>
          <fpage>187</fpage>
          <lpage>194</lpage>
          <year>1988</year>
          <pub-id pub-id-type="pmid">2828914</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Canals</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation</article-title>
          <source>J Biol Chem</source>
          <volume>287</volume>
          <fpage>650</fpage>
          <lpage>659</lpage>
          <year>2012</year>
          <pub-id pub-id-type="pmid">22086918</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leach</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sexton</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Christopoulos</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology</article-title>
          <source>Trends Pharmacol Sci</source>
          <volume>28</volume>
          <fpage>382</fpage>
          <lpage>389</lpage>
          <year>2007</year>
          <pub-id pub-id-type="pmid">17629965</pub-id>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ichiyama</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The structure of the third intracellular loop of the muscarinic acetylcholine receptor M2 subtype</article-title>
          <source>FEBS Lett</source>
          <volume>580</volume>
          <fpage>23</fpage>
          <lpage>26</lpage>
          <year>2006</year>
          <pub-id pub-id-type="pmid">16364317</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shapiro</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Nathanson</surname>
              <given-names>NM</given-names>
            </name>
          </person-group>
          <article-title>Deletion analysis of the mouse m1 muscarinic acetylcholine receptor: effects on phosphoinositide metabolism and down-regulation</article-title>
          <source>Biochemistry</source>
          <volume>28</volume>
          <fpage>8946</fpage>
          <lpage>8950</lpage>
          <year>1989</year>
          <pub-id pub-id-type="pmid">2557912</pub-id>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conrath</surname>
              <given-names>KE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae</article-title>
          <source>Antimicrob Agents Chemother</source>
          <volume>45</volume>
          <fpage>2807</fpage>
          <lpage>2812</lpage>
          <year>2001</year>
          <pub-id pub-id-type="pmid">11557473</pub-id>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whorton</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>104</volume>
          <fpage>7682</fpage>
          <lpage>7687</lpage>
          <year>2007</year>
          <pub-id pub-id-type="pmid">17452637</pub-id>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structural basis of G protein-coupled receptor-G protein interactions</article-title>
          <source>Nat Chem Biol</source>
          <volume>6</volume>
          <fpage>541</fpage>
          <lpage>548</lpage>
          <pub-id pub-id-type="doi">10.1038/nchembio.385</pub-id>
          <year>2010</year>
          <pub-id pub-id-type="pmid">20512139</pub-id>
        </element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Conklin</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Blin</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wess</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Identification of a receptor/G-protein contact site critical for signaling specificity and G-protein activation</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>92</volume>
          <fpage>11642</fpage>
          <lpage>11646</lpage>
          <year>1995</year>
          <pub-id pub-id-type="pmid">8524820</pub-id>
        </element-citation>
      </ref>
      <ref id="R42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid identification of functionally critical amino acids in a G protein-coupled receptor</article-title>
          <source>Nat Methods</source>
          <volume>4</volume>
          <fpage>169</fpage>
          <lpage>174</lpage>
          <year>2007</year>
          <pub-id pub-id-type="pmid">17206152</pub-id>
        </element-citation>
      </ref>
      <ref id="R43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McMillin</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Heusel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Costanzi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wess</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Structural basis of M3 muscarinic receptor dimer/oligomer formation</article-title>
          <source>J Biol Chem</source>
          <volume>286</volume>
          <fpage>28584</fpage>
          <lpage>28598</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M111.259788</pub-id>
          <year>2011</year>
          <pub-id pub-id-type="pmid">21685385</pub-id>
        </element-citation>
      </ref>
      <ref id="R44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caffrey</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cherezov</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Crystallizing membrane proteins using lipidic mesophases</article-title>
          <source>Nat Protoc</source>
          <volume>4</volume>
          <fpage>706</fpage>
          <lpage>731</lpage>
          <pub-id pub-id-type="doi">10.1038/nprot.2009.31</pub-id>
          <year>2009</year>
          <pub-id pub-id-type="pmid">19390528</pub-id>
        </element-citation>
      </ref>
      <ref id="R45">
        <label>45</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Otwinowski</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Minor</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <source>Methods in Enzymology</source>
          <volume>276</volume>
          <person-group person-group-type="editor">
            <name>
              <surname>Carter</surname>
              <given-names>Charles W</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <fpage>307</fpage>
          <lpage>326</lpage>
          <publisher-name>Academic Press</publisher-name>
          <year>1997</year>
        </element-citation>
      </ref>
      <ref id="R46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCoy</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phaser crystallographic software</article-title>
          <source>J Appl Crystallogr</source>
          <volume>40</volume>
          <fpage>658</fpage>
          <lpage>674</lpage>
          <pub-id pub-id-type="doi">10.1107/s0021889807021206</pub-id>
          <year>2007</year>
          <pub-id pub-id-type="pmid">19461840</pub-id>
        </element-citation>
      </ref>
      <ref id="R47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Afonine</surname>
              <given-names>PV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Towards automated crystallographic structure refinement with phenix.refine</article-title>
          <source>Acta Crystallogr Biol Crystallogr</source>
          <volume>D68</volume>
          <fpage>352</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="doi">10.1107/s0907444912001308</pub-id>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="R48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emsley</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cowtan</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Coot: model-building tools for molecular graphics</article-title>
          <source>Acta Crystallogr Biol Crystallogr</source>
          <volume>D60</volume>
          <fpage>2126</fpage>
          <lpage>2132</lpage>
          <year>2004</year>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <title>Isolation of Nb9-8</title>
        <p><bold>a</bold>, Nanobodies from a llama immunized with M<sub>2</sub> receptor were displayed on yeast as an amino terminal fusion to Aga2p, and subjected to magnetic selection to enrich clones that bind preferentially to agonist-occupied receptor. <bold>b</bold>, For selections, an aziridinium ion derivative of iperoxo called FAUC123 was synthesized, allowing covalent modification of the receptor. <bold>c</bold>, Yeast were stained simultaneously with agonist-occupied M<sub>2</sub> receptor and antagonist-occupied receptor labeled with distinct fluorophores. <bold>d</bold>, Yeast from each selection round (Rd. 1 â 9) were stained in this manner to assess selection progress, showing a clear enrichment first for non-selective binders (upper right quadrants) followed by specific enrichment for agonist-preferring clones (lower right quadrants). *Indicates a selection round employing conformational selection. **Indicates a selection round using FACS.</p>
      </caption>
      <graphic xlink:href="nihms529325f1"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <title>M<sub>2</sub> active-state specific nanobodies</title>
        <p><bold>a</bold>, Three nanobodies were selected for detailed characterization, each with entirely unique complementarity determining region (CDR) sequences. These three nanobodies were expressed on the surface of yeast, and characterized by flow cytometry staining with FAUC123-bound (<italic>i.e.</italic>, agonist-bound) M<sub>2</sub> receptor and tiotropium-bound (<italic>i.e.</italic>, antagonist-occupied) receptor. <bold>b</bold>, Each of the three clones displayed a preference for agonist-occupied receptor to varying degrees. <bold>c</bold>, Purified nanobodies were tested in a dose-response assay for their ability to suppress [<sup>3</sup>H]-NMS binding to the M<sub>2</sub> receptor in the presence of 10 nM (IC<sub>20</sub>) iperoxo, with Nb9-8 being the most potent clone. <bold>d</bold>, Like the G protein G<sub>i</sub>, Nb9-8 caused a substantial enhancement of iperoxo affinity in a competition binding assay.</p>
      </caption>
      <graphic xlink:href="nihms529325f2"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <title>Intracellular changes on activation of the M<sub>2</sub> receptor</title>
        <p><bold>a</bold>, The overall structure of the active-state M<sub>2</sub> receptor (orange) in complex with the orthosteric agonist iperoxo and the active-state stabilizing nanobody Nb9-8 is shown. <bold>b</bold>, Compared to the inactive structure of the M<sub>2</sub> receptor (blue), transmembrane helix 6 (TM6) is substantially displaced outward, and TM7 has moved inward. Together, these motions lead to the formation of the G protein-binding site. <bold>c-d</bold>, Conserved motifs likewise show substantial changes on activation, and adopt conformations similar to those seen in the two other active GPCR structures (<bold>e-f</bold>). In particular, an interaction between two conserved tyrosines (Tyr<sup>5.58</sup> and Tyr<sup>7.53</sup>) is likely mediated by a water molecule (blue circle), as seen in the high-resolution structure of the active Î²<sub>2</sub>AR [<xref rid="R18" ref-type="bibr">Ref. 18</xref>].</p>
      </caption>
      <graphic xlink:href="nihms529325f3"/>
    </fig>
    <fig id="F4" orientation="portrait" position="float">
      <label>Figure 4</label>
      <caption>
        <title>Orthosteric ligand binding site</title>
        <p><bold>a</bold>, Orthosteric ligands used for crystallization of inactive and active M<sub>2</sub> receptor are shown in. <bold>b</bold>, Cross-sections through the receptor are shown, with the interior in black. In the inactive conformation, the receptor (blue, at left) partially encloses the antagonist QNB, while the active conformation receptor encloses the agonist entirely, such that it is completely buried within the receptor (orange, at right). <bold>c</bold>, Conformational changes within the ligand binding pocket are shown from the extracellular side in, with changes highlighted as red arrows. <bold>d</bold>, A side view shows the inward motion of TM6, which is required for the formation of a hydrogen bond between Asn404<sup>6.52</sup> and the agonist iperoxo. <bold>e</bold>, Activation thus involves a pivot of TM6, which moves inward in the orthosteric site and outward at the intracellular side. <bold>f</bold>, The closure of the binding pocket allows the formation of a hydrogen bonded tyrosine lid, located superficial to the agonist.</p>
      </caption>
      <graphic xlink:href="nihms529325f4"/>
    </fig>
    <fig id="F5" orientation="portrait" position="float">
      <label>Figure 5</label>
      <caption>
        <title>Structure of a GPCR allosteric modulator complex</title>
        <p><bold>a</bold>, The M<sub>2</sub> receptor occupied by the orthosteric agonist iperoxo was crystallized in complex with the positive allosteric modulator LY2119620. <bold>b</bold>, The allosteric ligand binds to the extracellular vestibule just above the orthosteric agonist. A cross-section through the membrane plane shows the relative positions of the two ligands. <bold>c</bold>, Several polar contacts are involved in LY2119620 binding, in addition to extensive aromatic stacking interactions with Trp422<sup>7.35</sup> and Tyr177<sup>ECL2</sup>. <bold>d</bold>, Upon activation, the M<sub>2</sub> receptor undergoes substantial conformational changes in the extracellular surface, leading to a contraction of the extracellular vestibule. <bold>e</bold>, This creates a binding site that fits tightly around the allosteric modulator, which would otherwise be unable to interact extensively with the extracellular vestibule in the inactive receptor conformation.</p>
      </caption>
      <graphic xlink:href="nihms529325f5"/>
    </fig>
    <fig id="F6" orientation="portrait" position="float">
      <label>Extended Data Figure 1</label>
      <caption>
        <title>Characterization of FAUC123</title>
        <p><bold>a</bold>, Activation of M<sub>2</sub> receptor by the prototypical muscarinic agonist carbachol, the high affinity agonist iperoxo, and an irreversible iperoxo analog (FAUC 123) shows that iperoxo and FAUC 123 are exceptionally potent full agonists at the M<sub>2</sub> muscarinic receptor. Points indicate mean Â± SEM of three independent measurements, each performed in triplicate. <bold>b</bold>, <italic>Sf9</italic> membranes expressing the human M<sub>2</sub> receptor were incubated overnight at 4 Â°C with either no ligand, 100 Î¼M iperoxo, or 100 Î¼M FAUC 123. Membranes were then washed three times in buffer without ligand, and incubated with a saturating concentration (20 nM) of [<sup>3</sup>H]-NMS. Incubation with iperoxo had no effect on radioligand binding, while FAUC 123 blocked almost all [<sup>3</sup>H]-NMS binding sites. Bars indicate mean Â± SEM of three independent measurements. <bold>c</bold>, FAUC 123 was tested for its ability to induce M<sub>2</sub> receptor activation following covalent modification. While iperoxo-induced inositol phosphate production was blocked by 1 Î¼M atropine, FAUC 123-induced activation was not susceptible to atropine blockade. Bars indicate mean Â± SEM of three independent measurements.</p>
      </caption>
      <graphic xlink:href="nihms529325f6"/>
    </fig>
    <fig id="F7" orientation="portrait" position="float">
      <label>Extended Data Figure 2</label>
      <caption>
        <title>Comparison to other active GPCR structures</title>
        <p>Structures of all activated GPCRs show similarities in conformational changes at the intracellular surface. In each case, the intracellular tip of transmembrane helix 6 (TM6) moves outward on activation, as seen in the view from the intracellular side (right panels). This creates a cavity to which a G protein can bind the receptor.</p>
      </caption>
      <graphic xlink:href="nihms529325f7"/>
    </fig>
    <fig id="F8" orientation="portrait" position="float">
      <label>Extended Data Figure 3</label>
      <caption>
        <title>Pharmacology</title>
        <p><bold>a</bold>, Functional properties are shown for M<sub>2</sub> receptors in which key residues were mutated. Agonist-induced increases in intracellular calcium levels were monitored via FLIPR using transfected COS-7 cells. Since some mutant receptors (N58A, D103E) were expressed at lower levels than the WT receptor, reference curves were obtained using cells transfected with either 3 Î¼g DNA or 1 Î¼g WT receptor DNA. The latter cells showed receptor expression levels comparable to those found with the N58A and D103E mutants (see <xref rid="T2" ref-type="table">Extended Data Table 2</xref> for details). Data are given as means Â± SEM of three independent experiments, each carried out in triplicate. AU, arbitrary units. <bold>b</bold>, The interaction between LY2119620 and iperoxo was measured by radioligand binding and functional assays. LY2119620 enhances the affinity of iperoxo (top graph) and its signaling potency (bottom graphs), and is also able to directly activate M<sub>2</sub> receptor signaling as measured by [<sup>35</sup>S]GTPÎ³S and ERK1/2 phosphorylation. Experiments were carried out with CHO cells stably expressing the human M<sub>2</sub> receptor, and points are shown as mean Â± SEM of three independent experiments, each carried out in duplicate.</p>
      </caption>
      <graphic xlink:href="nihms529325f8"/>
    </fig>
    <fig id="F9" orientation="portrait" position="float">
      <label>Extended Data Figure 4</label>
      <caption>
        <title>Binding site diagram</title>
        <p>M<sub>2</sub> receptor residues interacting with the orthosteric agonist iperoxo and the positive allosteric modulator LY2119620 are shown. Polar contacts are highlighted as red dotted lines, and hydrophobic contacts are in green solid lines.</p>
      </caption>
      <graphic xlink:href="nihms529325f9"/>
    </fig>
    <fig id="F10" orientation="portrait" position="float">
      <label>Extended Data Figure 5</label>
      <caption>
        <title>Electron density</title>
        <p><bold>a-b</bold>, <italic>F<sub>o</sub>-F<sub>c</sub></italic> omit maps are shown in gray, contoured at 2.5 Ï within a 2.5 Ã radius of the indicated ligand. <bold>c-f</bold>, 2F<sub>o</sub>-F<sub>c</sub> maps are shown in blue, contoured at 1.5 Ï within a 2.0 Ã radius of the indicated region.</p>
      </caption>
      <graphic xlink:href="nihms529325f10"/>
    </fig>
    <fig id="F11" orientation="portrait" position="float">
      <label>Extended Data Figure 6</label>
      <caption>
        <title>Comparison of M<sub>2</sub> receptor structures with and without LY2119620 bound</title>
        <p>Comparison of the structure of active M<sub>2</sub> receptor with and without the allosteric modulator LY2119620 reveals that there are few differences outside the extracellular vestibule. Within the extracellular vestibule, there is a slight contraction in the presence of the modulator, and Trp422<sup>7.35</sup> undergoes a change of rotamer (panel b, red arrow).</p>
      </caption>
      <graphic xlink:href="nihms529325f11"/>
    </fig>
    <table-wrap id="T1" position="float" orientation="portrait">
      <label>Extended Data Table 1</label>
      <caption>
        <title>Data collection and refinement statistics</title>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th valign="top" align="left" rowspan="1" colspan="1"/>
            <th valign="top" align="center" rowspan="1" colspan="1">M<sub>2</sub> receptor:Nb9-8 complex</th>
            <th valign="top" align="center" rowspan="1" colspan="1">M<sub>2</sub> receptor:Nb9-8 complex bound to LY2119620</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Data collection</bold>
              <xref rid="TFN1" ref-type="table-fn">*</xref>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Number of crystals</td>
            <td align="center" valign="top" rowspan="1" colspan="1">17</td>
            <td align="center" valign="top" rowspan="1" colspan="1">18</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Space group</td>
            <td align="center" valign="top" rowspan="1" colspan="1">P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td>
            <td align="center" valign="top" rowspan="1" colspan="1">P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Unit cell dimensions</td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">â<italic>a, b, c</italic> (Ã)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">62.9,78.1,163.5</td>
            <td align="center" valign="top" rowspan="1" colspan="1">59.0,77.4,163.8</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">â<italic>Î±,Î²,Î³</italic>(Â°)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">90, 90, 90</td>
            <td align="center" valign="top" rowspan="1" colspan="1">90, 90, 90</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Resolution (Ã)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">33 â 3.5(3.6 â 3.5)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">36 â 3.7(3.8 â 3.7)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">R<sub>merge</sub> (%)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">18.8(74.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">19.5(60.5)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">&lt;l/Ïl&gt;</td>
            <td align="center" valign="top" rowspan="1" colspan="1">5.8(1.4)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">5.6(2.1)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">CC<sub>1/2</sub> (%)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">99.1 (35.0)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">99.0(54.1)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Completeness (%)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">95.9(83.1)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">93.0(80.1)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Redundancy</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4.8</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4.8</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <bold>Refinement</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Number of reflections</td>
            <td align="center" valign="top" rowspan="1" colspan="1">10237</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7867</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">R<sub>work</sub>/R<sub>free</sub> (%)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">24.9 / 29.8</td>
            <td align="center" valign="top" rowspan="1" colspan="1">25.0 / 30.1</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">No. atoms</td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âProtein</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3020</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3013</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âLigand(s)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">14</td>
            <td align="center" valign="top" rowspan="1" colspan="1">57</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Average B factors (Ã<sup>2</sup>)</td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âReceptor</td>
            <td align="center" valign="top" rowspan="1" colspan="1">109.7</td>
            <td align="center" valign="top" rowspan="1" colspan="1">102.3</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âNb6B9</td>
            <td align="center" valign="top" rowspan="1" colspan="1">137.4</td>
            <td align="center" valign="top" rowspan="1" colspan="1">129.3</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âIperoxo</td>
            <td align="center" valign="top" rowspan="1" colspan="1">105.5</td>
            <td align="center" valign="top" rowspan="1" colspan="1">107.6</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âLY2119620</td>
            <td align="center" valign="top" rowspan="1" colspan="1">-</td>
            <td align="center" valign="top" rowspan="1" colspan="1">119.0</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">RMS deviation from ideality</td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âBond length (Ã)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.004</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.004</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âBond angles (Â°)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.86</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.81</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Ramachandran statistics<xref rid="TFN2" ref-type="table-fn">â </xref></td>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
            <td align="center" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âFavored (%)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">97.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">95.9</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âAllowed (%)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">3.0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4.1</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âOutliers (%)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN1">
          <label>*</label>
          <p>Highest shell statistics in parentheses.</p>
        </fn>
        <fn id="TFN2">
          <label>â </label>
          <p>As calculated by Molprobity.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T2" position="float" orientation="portrait">
      <label>Extended Data Table 2</label>
      <caption>
        <title>Ligand binding properties of mutant M<sub>2</sub> receptors</title>
        <p>Radioligand binding studies were carried out with membranes prepared from COS-7 cells transiently expressing the indicated mutant M<sub>2</sub> receptor constructs. The WT M<sub>2</sub> receptor was expressed at two different densities to allow for a more straightforward interpretation of the functional data shown in <xref rid="SD1" ref-type="supplementary-material">Supplementary Fig. 6</xref> (see Online Methods for details). ACh and iperoxo binding affinities (K<sub>i</sub>) were determined in radioligand competition binding assays as indicated. ACh and iperoxo binding affinities (K<sub>i</sub>) were determined in [<sup>3</sup>H]-QNB competition binding assays for the N404Q<sup>6.52</sup> mutant, which did not bind [<sup>3</sup>H]-NMS with sufficient affinity. Data are given as means Â± SEM from two or three independent experiments, each performed in duplicate.</p>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th align="left" valign="middle" rowspan="3" colspan="1">Receptor</th>
            <th colspan="2" align="center" valign="middle" rowspan="1">[<sup>3</sup>H]-NMS binding</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">ACh binding</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Iperoxo binding</th>
          </tr>
          <tr>
            <th align="center" valign="middle" rowspan="1" colspan="1">K<sub>D</sub></th>
            <th align="center" valign="middle" rowspan="1" colspan="1">B<sub>max</sub></th>
            <th align="center" valign="middle" rowspan="1" colspan="1">K<sub>i</sub></th>
            <th align="center" valign="middle" rowspan="1" colspan="1">K<sub>i</sub></th>
          </tr>
          <tr>
            <th align="center" valign="middle" rowspan="1" colspan="1">nM</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">pmol/mg of protein</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Î¼M</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Î¼M</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">WT M2</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.48 Â± 0.31</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.79 Â± 0.17</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">2.74 Â± 0.13</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">0.0073 Â± 0.0006</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">WT M<sub>2</sub>(1 Î¼g DNA)</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.40 Â± 0.02</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">0.60 Â±0.14</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1"/>
            <td align="center" valign="bottom" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">N58A<sup>2.39</sup></td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.15 Â± 0.05</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">0.62 Â± 0.14</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">0.84 Â± 0.21</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">0.0053 Â± 0.0012</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">D103E<sup>3.32</sup></td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">2.57 Â± 0.58</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">0.51 Â± 0.10</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">327 Â± 91</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">2.76 Â± 0.82</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">Y206F<sup>5.58</sup></td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.67 Â± 0.26</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.87 Â± 0.26</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">31.8 Â±0.71</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">0.52 Â± 0.20</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">N404Q<sup>6 52</sup></td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">N.D.<xref rid="TFN3" ref-type="table-fn">*</xref></td>
            <td align="center" valign="bottom" rowspan="1" colspan="1"/>
            <td align="center" valign="bottom" rowspan="1" colspan="1"/>
            <td align="center" valign="bottom" rowspan="1" colspan="1"/>
          </tr>
        </tbody>
      </table>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th align="left" valign="middle" rowspan="3" colspan="1">Receptor</th>
            <th align="center" valign="middle" colspan="2" rowspan="1">[<sup>3</sup>H]-QNB binding</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">ACh binding</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Iperoxo binding</th>
          </tr>
          <tr>
            <th align="center" valign="middle" rowspan="1" colspan="1">K<sub>D</sub></th>
            <th align="center" valign="middle" rowspan="1" colspan="1">B<sub>max</sub></th>
            <th align="center" valign="middle" rowspan="1" colspan="1">K<sub>i</sub></th>
            <th align="center" valign="middle" rowspan="1" colspan="1">K<bold><sub>i</sub></bold></th>
          </tr>
          <tr>
            <th align="center" valign="middle" rowspan="1" colspan="1">nM</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">pmol/mg of protein</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Î¼M</th>
            <th align="center" valign="middle" rowspan="1" colspan="1">Î¼M</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">WT M<sub>2</sub></td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">0.058 Â± 0.015</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.63 Â± 0.19</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.25 Â± 0.07</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">0.0130 Â± 0.0070</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" rowspan="1" colspan="1">N404Q<sup>6.52</sup></td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">9.47 Â± 2.22</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.24 Â± 0.12</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">34.3 Â± 10.3</td>
            <td align="center" valign="bottom" rowspan="1" colspan="1">1.70 Â± 0.29</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN3">
          <label>*</label>
          <p>no detectable [<sup>3</sup>H]-NMS binding activity</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T3" position="float" orientation="portrait">
      <label>Extended Data Table 3</label>
      <caption>
        <title>Pharmacological characterization of LY2119620</title>
        <p><bold>a</bold>, Allosteric ternary complex model binding parameters for the interaction between LY2119620, iperoxo, and [<sup>3</sup>H]-NMS at the human M<sub>2</sub> receptor. <bold>b</bold>, Operational model parameters for the functional allosteric interaction between iperoxo and LY2119620 at the human M<sub>2</sub> receptor. Estimated parameter values represent the mean Â± SEM of three experiments performed in duplicate.</p>
      </caption>
      <table frame="below" rules="groups">
        <thead>
          <tr>
            <th colspan="3" align="left" valign="bottom" rowspan="1">a
<hr/></th>
          </tr>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">Parameter</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Value</th>
            <th align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" colspan="" rowspan="1">pK<sub>B</sub><xref rid="TFN4" ref-type="table-fn">*</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">5.77 Â± 0.10</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pK<sub>|</sub><xref rid="TFN5" ref-type="table-fn">â </xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">8.51 Â± 0.04</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">LogÎ±<xref rid="TFN6" ref-type="table-fn">â¡</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">1.40 Â± 0.09 (Î± = 25)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">LogÎ±'<xref rid="TFN7" ref-type="table-fn">Â§</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">-0.26 Â± 0.03 (Î±' = 0.6)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
          </tr>
        </tbody>
      </table>
      <table frame="below" rules="groups">
        <thead>
          <tr>
            <th colspan="3" align="left" valign="bottom" rowspan="1">b
<hr/></th>
          </tr>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">Parameter</th>
            <th align="left" valign="top" rowspan="1" colspan="1">[<sup>35</sup>S]GTPÎ³S</th>
            <th align="left" valign="top" rowspan="1" colspan="1">ERK1/2</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">pK<sub>B</sub><xref rid="TFN4" ref-type="table-fn">*</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">5.73 Â± 0.11</td>
            <td align="left" valign="top" rowspan="1" colspan="1">5.84 Â± 0.18</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">logÎ±Î² <xref rid="TFN8" ref-type="table-fn">â</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">1.42 Â± 0.09</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1.30 Â± 0.20</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"/>
            <td align="left" valign="top" rowspan="1" colspan="1">(Î±Î² = 26)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">(Î±Î² = 20)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">logÏ<sub>B</sub><xref rid="TFN9" ref-type="table-fn">Â¶</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">-0.28 Â± 0.05</td>
            <td align="left" valign="top" rowspan="1" colspan="1">0.33 Â± 0.09</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN4">
          <label>*</label>
          <p>Negative logarithm of the equilibrium dissociation constant of LY2119620</p>
        </fn>
        <fn id="TFN5">
          <label>â </label>
          <p>Negative logarithm of the equilibrium dissociation constant of iperoxo</p>
        </fn>
        <fn id="TFN6">
          <label>â¡</label>
          <p>Logarithm of the binding cooperativity factor between LY2119620 and iperoxo (antilogarithm shown in parentheses)</p>
        </fn>
        <fn id="TFN7">
          <label>Â§</label>
          <p>Logarithm of the binding cooperativity factor between LY2119620 and [<sup>3</sup>H]-NMS (antilogarithm shown in parentheses)</p>
        </fn>
        <fn id="TFN8">
          <label>â</label>
          <p>Logarithm of the product of the binding cooperativity (Î±) and activation modulation (Î²) factors between iperoxo and LY2119620. Antilogarithm shown in parentheses.</p>
        </fn>
        <fn id="TFN9">
          <label>Â¶</label>
          <p>Logarithm of the operational efficacy parameter of LY2119620 as an allosteric agonist.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>